A literature search was performed identifying clinical trials of semaglutide published until 01 Dec 2023
The findings support the use of once-weekly subcutaneous semaglutide at a dose of 2.4 mg for weight management and treatment of pain in persons with obesity and moderate to severe pain due to knee osteoarthritis.
Think nausea, bloating, cramps, or abdominal pain
Always discuss your personal risks, benefits, and preferences with your healthcare provider before starting or switching medications
Tirzepatide is a single novel molecule that activates the bodys receptors for GIP and GLP-1, which are natural incretin hormones
This can cause symptoms such as dizziness, confusion, sweating, and even loss of consciousness